Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886988 | 0.84 | NOTUM (0.51) | SMN1; SMN2CYP1A2NOTUMMAPK8AR | |
| SCHEMBL14810395 | 0.75 | MAPK8 (0.46) | SMN1; SMN2CYP1A2MAPK8BRD4BRD2 | |
| SCHEMBL10068017 | 0.74 | CYP1A2 (0.50) | SMN1; SMN2CYP1A2MAPK8ARDAPK3 | |
| SCHEMBL23408461 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2MAPK8ALDH1A1TP53 | |
| SCHEMBL1243976 | 0.74 | CNR2 (0.55) | SMN1; SMN2CYP1A2NOTUMARKDM4E | |
| SCHEMBL3941669 | 0.73 | KDM4E (0.51) | SMN1; SMN2CYP1A2MAPK8ARALDH1A1 | |
| SCHEMBL4273292 | 0.72 | NOTUM (0.52) | NOTUMMAPK8ARKDM4EBRD4 | |
| SCHEMBL4150352 | 0.72 | PKM (0.62) | SMN1; SMN2CYP1A2MAPK8ALDH1A1HSP90AA1 | |
| SCHEMBL23094452 | 0.72 | MAPK14 (0.52) | SMN1; SMN2NOTUMALDH1A1HSD17B10KDM4E | |
| SCHEMBL182807 | 0.72 | MAPK8 (0.57) | SMN1; SMN2CYP1A2MAPK8ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946554-B2 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0970029-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5650511-A | MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997021653-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | SMN1; SMN2 2036/4885CYP1A2 3591/4885NOTUM 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.